Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.75Last Year’s EPS
-0.63Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results, regulatory progress, and financial stability, indicating positive momentum for Kura Oncology's lead program, ziftomenib, and its pipeline. However, increased expenses and net loss present financial challenges. The sentiment is positive overall due to significant advancements and strong financial positioning.Company Guidance
Positive Data from KOMET-001 Trial
Ziftomenib showed promising results in relapsed or refractory NPM1-mutated AML with a CR/CRh rate of 23% and 63% of responders being MRD negative.
FDA Priority Review
FDA accepted the NDA for ziftomenib with a PDUFA target action date of November 30, 2025, indicating positive regulatory progress.
Strong Financial Position
Kura Oncology has $630.7 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into 2027.
Advancements in Pipeline
Progress with next-generation farnesyl transferase inhibitor, KO-2806, with three clinical abstracts accepted for presentation at the 2025 ESMO Congress.
Commercial Readiness for Ziftomenib
Preparations for potential approval are underway, including the building of commercial supply, quality systems, and a sales force.
KURA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KURA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $5.96 | $5.54 | -7.05% |
May 01, 2025 | $6.49 | $6.47 | -0.31% |
Feb 26, 2025 | $7.77 | $7.65 | -1.54% |
Nov 07, 2024 | $17.77 | $17.68 | -0.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kura Oncology (KURA) report earnings?
Kura Oncology (KURA) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is Kura Oncology (KURA) earnings time?
Kura Oncology (KURA) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KURA EPS forecast?
KURA EPS forecast for the fiscal quarter 2025 (Q3) is -0.75.